Despite recent advances, still little is known about TIGIT-CD155/CD112 axis in myeloid leukemias and additional studies are needed to implement a novel therapeutic strategy with the use of blocking antibodies. The gene discussed is NECTIN2; the disease is myeloid leukemia.